ansuvimab

Ansuvimab is a fully human monoclonal IgG1 antibody developed for the treatment of infection caused by Zaire ebolavirus (Ebola virus). It was originally derived from B-cells of a survivor of the 1995 Kikwit Ebola outbreak. Ansuvimab binds with high affinity to a conserved region on the GP1,2 envelope glycoprotein of Zaire ebolavirus, specifically targeting an epitope in the receptor-binding domain (RBD) that interacts with the host cell Niemann-Pick C1 (NPC1) protein. By blocking this interaction, ansuvimab prevents viral entry into host cells and neutralizes infectivity. Additionally, it mediates antibody-dependent cell-mediated cytotoxicity (ADCC), contributing to clearance of infected cells. Ansuvimab demonstrated superior efficacy compared to other investigational therapies in clinical trials and received FDA approval in December 2020 for use in adults and pediatric patients with Ebola virus disease[1][4][5][6][7].

Brand names

Ebanga

Other names

ansuvimab-zykl